We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: 0.05 (3.13%)
Spread: 0.10 (6.25%)
Open: 1.60
High: 1.80
Low: 1.55
Prev. Close: 1.60
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

25 Apr 2013 16:59

RNS Number : 2822D
Flying Brands Limited
25 April 2013
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Flying Brands ltd

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Henderson Global Investors

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

11 January 2013

6. Date on which issuer notified:

15 January 2013

7. Threshold(s) that is/are crossed orreached: vi, vii

16%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

1,847,309

1,847,309

Below 5%

Below 5%

GB0003437059

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Below 5%

Below 5%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

 

 

14. Contact name:

Balenkosi Dungeni

15. Contact telephone number:

020 7818 3747

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLSEIFIIFDSEIL
Date   Source Headline
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.